Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Huntington disease. The agreement covers the territory of Russian federation and is valid for 5 years with relevant milestones. Farmamondo’s local affiliate will be responsible to achieve Marketing Authorization and commercially champion the launch of the product to Russian patients.
About Farmamondo: Farmamondo is a Swiss-based pharmaceutical company with a focus on providing patient access to their unmet medical need via Early-access, Named-patient and Compassionate-use programs. Our global footprint includes commercial operations in more than 50 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
About AOP Orphan: AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. As a specialist in Orphan Diseases, AOP Orphan researches, develops, produces, and distributes innovative solutions in the following therapeutic areas: hematology and oncology, cardiology and pulmonology, neurology and psychiatry, and metabolic diseases.
